HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT02751307

Metformin Dose for Metabolic Changes With Clozapine in Schizophrenia

About this titleRead the official source — NCT02751307
Medication studyAges 20–65
The study in practice

Understand this study

Who was this study for?

Listed age limits: 20 years to 65 years.

Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2013
Recruitment status
Completed
Enrollment listed in the registry
55
Sponsor
Taipei Medical University WanFang Hospital
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Not clearly listed
Age range
From 20 Years to 65 Years
Official registry ID
NCT02751307
Official title
Show the full official title

Treatment of Metabolic Abnormalities in Patients With Schizophrenia: Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Taipei Medical University WanFang Hospital, a university.

Did this study involve medication?

Yes. The study involved medication, including metformin 500 mg and clozapine 100 mg.

Who was this study for?

Listed age limits: 20 years to 65 years.

Want to explore more studies?

Explore studies